APLS Stock Recent News

APLS LATEST HEADLINES

APLS Stock News Image - zacks.com

Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.

zacks.com 2024 Jun 11
APLS Stock News Image - zacks.com

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?

zacks.com 2024 Jun 06
APLS Stock News Image - globenewswire.com

WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET.

globenewswire.com 2024 Jun 05
APLS Stock News Image - zacks.com

Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.

zacks.com 2024 May 27
APLS Stock News Image - globenewswire.com

WALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced positive one-year results from the Phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These data were presented during a late-breaking oral presentation at the European Renal Association (ERA) Congress taking place May 23-26 in Stockholm, Sweden.

globenewswire.com 2024 May 24
APLS Stock News Image - Zacks Investment Research

Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.

Zacks Investment Research 2024 May 07
APLS Stock News Image - Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.54 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.56 per share a year ago.

Zacks Investment Research 2024 May 07
APLS Stock News Image - Invezz

Apellis Pharmaceuticals Inc (NASDAQ: APLS) is down nearly 40% versus its year-to-date high but a Mizuho analyst does not see it as an opportunity to buy per se. Mizuho remains ‘neutral' on Apellis Pharmaceuticals stock Graig Suvannavejh reiterated his “neutral” stance on the biotech stock in a recent research note.

Invezz 2024 Apr 30
APLS Stock News Image - Zacks Investment Research

Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research 2024 Apr 30
APLS Stock News Image - Zacks Investment Research

Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.

Zacks Investment Research 2024 Feb 28
10 of 50